These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10706968)

  • 1. Humoral immunoresponse to varicella-zoster virus pernasally coadministered with Escherichia coli enterotoxin in mice.
    Tsuji T; Shiraki K; Sato H; Yue-Mea J; Honma Y; Yoshikawa T; Asano Y
    Vaccine; 2000 Apr; 18(19):2049-54. PubMed ID: 10706968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant action of Escherichia coli enterotoxin for delayed-type hypersensitivity to Oka vaccine virus on pernasal co-administration in mice.
    Sasaki K; Asano Y; Honma Y; Kamiya N; Handa T; Ichinose Y; Yokochi T; Shiraki K; Tsuji T
    Vaccine; 2000 Nov; 19(7-8):931-6. PubMed ID: 11115718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term persistence of cellular immunity to Oka vaccine virus induced by pernasal co-administration with Escherichia coli enterotoxin in mice.
    Kamiya N; Asano Y; Yoshino J; Sasaki K; Honma Y; Kawase H; Yokochi T; Shiraki K; Tsuji T
    Vaccine; 2001 Apr; 19(23-24):3131-6. PubMed ID: 11312008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of cellular immunity to varicella-zoster virus glycoproteins tested with pernasal coadministration of Escherichia coli enterotoxin in mice.
    Tsuji T; Shiraki K; Sato H; Sasaki K; Arita M; Kato M; Takahashi T; Ochi S; Ichinose Y; Yokochi T; Asano Y
    J Med Virol; 2003 Mar; 69(3):451-8. PubMed ID: 12526058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of glycoprotein E subunit and live attenuated varicella-zoster virus vaccines formulated with a single-strand RNA-based adjuvant.
    Lee SJ; Park HJ; Ko HL; Lee JE; Lee HJ; Kim H; Nam JH
    Immun Inflamm Dis; 2020 Jun; 8(2):216-227. PubMed ID: 32167678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial.
    Trannoy E; Berger R; Holländer G; Bailleux F; Heimendinger P; Vuillier D; Creusvaux H
    Vaccine; 2000 Feb; 18(16):1700-6. PubMed ID: 10689152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers.
    Stephenson I; Zambon MC; Rudin A; Colegate A; Podda A; Bugarini R; Del Giudice G; Minutello A; Bonnington S; Holmgren J; Mills KH; Nicholson KG
    J Virol; 2006 May; 80(10):4962-70. PubMed ID: 16641287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient induction of cell-mediated immunity to varicella-zoster virus glycoprotein E co-lyophilized with a cationic liposome-based adjuvant in mice.
    Wui SR; Kim KS; Ryu JI; Ko A; Do HTT; Lee YJ; Kim HJ; Lim SJ; Park SA; Cho YJ; Kim CG; Lee NG
    Vaccine; 2019 Apr; 37(15):2131-2141. PubMed ID: 30827737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA.
    Gerber S; Lane C; Brown DM; Lord E; DiLorenzo M; Clements JD; Rybicki E; Williamson AL; Rose RC
    J Virol; 2001 May; 75(10):4752-60. PubMed ID: 11312347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal delivery of a respiratory syncytial virus CTL peptide with enterotoxin-based adjuvants elicits protective, immunopathogenic, and immunoregulatory antiviral CD8+ T cell responses.
    Simmons CP; Hussell T; Sparer T; Walzl G; Openshaw P; Dougan G
    J Immunol; 2001 Jan; 166(2):1106-13. PubMed ID: 11145691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the immunogenicity of a transgenic tobacco plant expressing the recombinant fusion protein of GP5 of porcine reproductive and respiratory syndrome virus and B subunit of Escherichia coli heat-labile enterotoxin in pigs.
    Chia MY; Hsiao SH; Chan HT; Do YY; Huang PL; Chang HW; Tsai YC; Lin CM; Pang VF; Jeng CR
    Vet Immunol Immunopathol; 2011 Apr; 140(3-4):215-25. PubMed ID: 21277027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity.
    Weinberg A; Pang L; Johnson MJ; Caldas Y; Cho A; Tovar-Salazar A; Canniff J; Schmader KE; Popmihajlov Z; Levin MJ
    J Virol; 2019 Aug; 93(15):. PubMed ID: 31092579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mutant of Escherichia coli enterotoxin inducing a specific Thl-type of T cells to varicella-zoster vaccine enhances the production of IL-12 by IFNgamma-stimulated macrophages.
    Shimizu T; Sasaki K; Kato M; Arimitsu H; Ochi S; Yano T; Oguma K; Yokochi T; Tsuji T
    Vaccine; 2006 May; 24(18):3719-26. PubMed ID: 16115702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal immunogenicity and adjuvant activity of the recombinant A subunit of the Escherichia coli heat-labile enterotoxin.
    De Haan L; Holtrop M; Verweij WR; Agsteribbe E; Wilschut J
    Immunology; 1999 Aug; 97(4):706-13. PubMed ID: 10457227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the LTK63 adjuvant effect on cellular immune responses to measles virus nucleoprotein.
    Erume J; Partidos CD
    Afr Health Sci; 2011 Jun; 11(2):151-7. PubMed ID: 21857843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunity to whole varicella-zoster virus antigen and glycoproteins I and p170: relation to the immunizing regimen of live attenuated varicella vaccine.
    Diaz PS; Smith S; Hunter E; Arvin AM
    J Infect Dis; 1988 Dec; 158(6):1245-52. PubMed ID: 2848901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Live varicella vaccine polarizes the mucosal adjuvant action of cholera toxin or its B subunit on specific Th1-type helper T cells with a single nasal coadministration in mice.
    Sasaki K; Kato M; Takahashi T; Ochi S; Ichinose Y; Shiraki K; Asano Y; Iwanaga M; Tsuji T
    J Med Virol; 2003 Jun; 70(2):329-35. PubMed ID: 12696126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults.
    Leroux-Roels I; Leroux-Roels G; Clement F; Vandepapelière P; Vassilev V; Ledent E; Heineman TC
    J Infect Dis; 2012 Oct; 206(8):1280-90. PubMed ID: 22872734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of mutant Escherichia coli heat-labile enterotoxin (LT H44A) as an adjuvant for nasal influenza vaccine.
    Hagiwar Y; Tsuji T; Iwasaki T; Kadowaki S; Asanuma H; Chen Z; Komase K; Suzuki Y; Aizawa C; Kurata T; Tamura S
    Vaccine; 2001 Feb; 19(15-16):2071-9. PubMed ID: 11228379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.
    Grupping K; Campora L; Douha M; Heineman TC; Klein NP; Lal H; Peterson J; Vastiau I; Oostvogels L
    J Infect Dis; 2017 Dec; 216(11):1343-1351. PubMed ID: 29029122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.